Leyden Laboratories BV, a Dutch start-up, has launched an ambitious plan to develop a portfolio of intranasal prophylactic medicines to prevent infection from a host of viruses including coronaviruses. On 25 March, the company announced the closing of a Series A financing of €40 million from a syndicate led by GV (formerly Google Ventures), to advance its programme.
In a statement, Koenraad Wiedhaup, chief executive of the new company, said the goal is to “develop products that provide immediate protection against existing, mutating and new viruses.”